Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study explores the potential value of a new blood test approach for early detection of cancer.
Eligibility criteria
Qualifiers
Aim 1 Tissue
Patient has a biopsy confirmed diagnosis of target histology
Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without
Disqualifiers
Aim 1 Tissue
Patient has had any transplants prior to tissue collection
Patient has received chemotherapy class drugs within 5 years prior to tissue collection
Patient has had radiation to the current target lesion prior to tissue collection
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
6,150 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov